Technology area: Biotechnology & Pharmaceuticals
5 pending office actions • 5 art units • 5 examiners • 0 of 5 (0%) have an AI response strategy ready
Etherna Immunotherapies NV has 5 pending office actions in Biotechnology & Pharmaceuticals. The matters are distributed among 5 distinct examiners and 5 distinct art units, requiring separate attention to each examination assignment.
FALKOWITZ, ANNA R is the busiest examiner, with 1 pending matter. Because the recorded matters are evenly distributed by examiner, counsel should use a common biotechnology claim strategy while preparing distinct responses to the objections in each record.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 2 (40%) |
| Double-patenting + other | 1 (20%) |
| Multi-statute (no §101) | 1 (20%) |
| No statute on record | 1 (20%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| FALKOWITZ, ANNA R | 1 | 55.7% | +45.3% |
| BECKHARDT, LYNDSEY MARIE | 1 | 27.8% | +48.0% |
| PRONZATI, GINA | 1 | 65.9% | +48.3% |
| YU, DELPHINUS DOU YI | 1 | 33.3% | +0.0% |
| PATTERSON, SARAH COOPER | 1 | 56.1% | +51.5% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18719001 | METHOD FOR LAGRE-SCALE PRODUCTION OF LARGE-SIZE LNPs | BECKHARDT, LYNDSEY MARIE | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18561862 | METHODS FOR STORING MRNA COMPOSITIONS | PRONZATI, GINA | 8d overdue |
| 17420556 | mRNA Vaccine | PATTERSON, SARAH COOPER | 34d |
| 18866766 | IONIZABLE LIPIDS | FALKOWITZ, ANNA R | — |
| 18719001 | METHOD FOR LAGRE-SCALE PRODUCTION OF LARGE-SIZE LNPs | BECKHARDT, LYNDSEY MARIE | — |
| Art Unit | Apps |
|---|---|
| 1600 | 1 |
| 1613 | 1 |
| 1633 | 1 |
| 1636 | 1 |
| 1675 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18866766 | IONIZABLE LIPIDS | FALKOWITZ, ANNA R | 1600 | §102§112DP | Non-Final OA | — | Pending | Nov 18, 2024 |
| 18719001 | METHOD FOR LAGRE-SCALE PRODUCTION OF LARGE-SIZE LNPs | BECKHARDT, LYNDSEY MARIE | 1613 | §103§112 | Non-Final OA | — | Pending | Jun 12, 2024 |
| 18561862 | METHODS FOR STORING MRNA COMPOSITIONS | PRONZATI, GINA | 1633 | §103 | Final Rejection | 8d overdue | Pending | Nov 17, 2023 |
| 18561864 | METHOD TO REDUCE DOUBLE STRANDED RNA BY-PRODUCT FORMATION | YU, DELPHINUS DOU YI | 1636 | §103 | Final Rejection | — | Pending | Nov 17, 2023 |
| 17420556 | mRNA Vaccine | PATTERSON, SARAH COOPER | 1675 | Other | Final Rejection | 34d | Pending | Jul 02, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialEtherna Immunotherapies NV has 5 pending office actions as of October 2026, spread across 5 art units and 5 examiners.
Anna R Falkowitz has the most, with 1 of Etherna Immunotherapies NV's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
